Get a Deep Insight into the World Gene Therapy Market

Business Wire, Dec 16, 2008

NEW YORK -- Reportlinker.com announces that a new market research report related to the Biotechnologies and Genetics industry is available in its catalogue.

World Gene Therapy Market

http://www.reportlinker.com/p098244/World-Gene-Therapy--Market.html

This report analyzes the world market for Gene Therapy in Millions of US$. Annual forecasts are provided for the global market for the period of 2007 through 2015. The report profiles 100 companies including many key and niche players worldwide such as AnGes MG Inc., Cell Genesys, GenVec, Genzyme Corporation, Introgen Therapeutics Inc., Oxford BioMedica, Shenzhen SiBiono GeneTech Co., Ltd., Targeted Genetics Corp., Transgene, Urigen Pharmaceuticals Inc., and Vical. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

GENE THERAPY MCP-1127 A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-2 Product Definitions and Scope of Study I-3

II. A GLOBAL MARKET REPORT

1. Market Dynamics II-1 Future - On a Promising Note II-1 Market Predictions Thrive On II-1 China - First to Hit the Market II-1 Counting on the Success Factors II-1 Global Market Analysis II-2

Table 1: World Current & Future Market Analysis for Gene Therapy -Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart) II-2

2. Key Issues/ Trends II-3 Factors Influencing Gene Therapy Future Development II-3 Human Genome Analysis II-3 Gene Therapy - The Next Generation Cardiovascular Therapy II-3 Public Support for Gene Therapy II-3 RNAi Bode Bright Prospects II-3 Factors Hampering Market Growth II-3 Stringent Regulatory Laws in US and Europe Prolongs Gene Therapy Development II-3 Identifying Genetic Fault II-4 Immune Response II-4 Delivering Genetic Materials into Patient Cells II-4 Multigene Disorders II-5 Side Effects II-5 Push Towards Germline Gene Transfer II-5 Technical Limitations II-5

3. The Global Landscape II-6 Alliances and Acquisitions - Strategy to Success II-6 Patent Pooling: Yet Another Obstacle II-6 Commercialization: A Road Uphill II-6 Time Line in Gene Therapy Drug Development II-7 Target Diseases and Players Involved II-7 Key Players by Application Area II-7

Table 2: Gene Therapy Clinical Trials Worldwide (2007): Percentage Breakdown by Disease/ Application Area for Cancer, Heart Disease, Monogenic Diseases, Infectious Diseases and Others (includes corresponding Graph/Chart) II-8

Table 3: Gene Therapy Clinical Trials Worldwide (2007): Percentage Breakdown by Gene Type Transferred for Antigen, Cytokine, Tumor Suppressor, Growth Factor, Suicide, Deficiency and Others (includes corresponding Graph/Chart) II-8

Table 4: Gene Therapy Clinical Trials Worldwide (2007): Percentage Breakdown by Vector Type for Adenovirus, Retrovirus, Naked/Plasmid DNA, Lipofection, Vaccinia Virus, Poxvirus, Adeno-associated Virus and Others (includes corresponding Graph/Chart) II-9

Table 5: Gene Therapy Clinical Trials Worldwide (2007): A Split by Development Phase (includes corresponding Graph/Chart) II-9

Table 6: Gene Therapy Clinical Trials (2007): Percentage Breakdown by Geographic Region for US, Europe, Canada, Japan and Rest of World (includes corresponding Graph/Chart) II-9 Various Gene Therapy Products Under Development (2007) II-10 Gene Therapy Industry in Europe and the US - A Comparison II-10

4. Review of Major Markets II-12 United States II-12 Regulatory Environment II-12 Food and Drug Administration II-12 IRB and IBC II-13 NIH II-13 Europe II-14 Germany and UK- The Hub of European Gene Therapy Market II-14

Table 7: Gene Therapy Clinical Trials in Europe (2007): Percentage Breakdown of Number of Trials by Country for UK, Germany, Switzerland, France, Belgium, Netherlands and Others (includes corresponding Graph/Chart) II-15 Regulatory Environment II-15 Gene Therapy Advisory Committee II-15 European Society of Gene and Cell Therapy (ESGCT) II-16 Study of Regulatory Environment in Select European Countries II-16 United Kingdom II-16 Germany II-16 Italy II-16 Sweden II-16 The Netherlands II-17 Switzerland II-17 Japan II-17 Asia-Pacific II-17 World's First Gene Therapy Medicine Approved in China II-17 Prospects for Gendicine II-18 Competition II-18 Rest of World II-18

5. Gene Therapy - An Insight II-19 Molecular Basics - The Gene II-19 Genome - The Information Pool II-19 Functional cloning II-19 Random sequencing II-19 Positional cloning. II-20 What is Gene Therapy? II-20 A Backdrop II-20 1990 Highlights - The Preliminary Gene Therapy Trial II-20 1995 Highlights II-20 2000 Highlights - Clinical Trials Reaches 400- Milestone II-20 2004 Witnesses the First Gene Therapy Drug II-21 Classical Theory of Gene Therapy II-21 Ex-Vivo Approach of Gene Therapy II-21 In-vivo Approach of Gene Therapy II-21 Types of Gene Therapy II-21 Monogenic Gene Therapy II-21 Suicide Gene Therapy II-22 Antisense Gene Therapy II-22 Various Approaches II-22